Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066669 | 0.92 | F10 (0.58) | F10 | |
| SCHEMBL5088106 | 0.90 | F10 (0.63) | F10HDAC8LMNA | |
| SCHEMBL6066458 | 0.88 | F10 (0.53) | F10 | |
| SCHEMBL5093819 | 0.86 | F10 (0.62) | F10HDAC8 | |
| SCHEMBL6066445 | 0.83 | F10 (0.54) | F10LMNA | |
| SCHEMBL6066494 | 0.82 | F10 (0.54) | F10 | |
| SCHEMBL6066457 | 0.81 | F10 (0.60) | F10 | |
| SCHEMBL6871677 | 0.81 | F10 (0.47) | F10 | |
| SCHEMBL6066471 | 0.80 | HDAC8 (0.56) | F10HDAC8LMNA | |
| SCHEMBL31096065 | 0.79 | HSD17B2 (0.64) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228039-B1 | N-GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6664393-B2 | Anticoagulants | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-16 | — | — | US | disclosed |
| US-20030162967-A1 | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-08-28 | — | — | US | disclosed |
| US-6472562-B1 | SUCH AS 4-NITRO-N-(1-CARBAMOYL-4-GUANIDINOBUTYL)-3-(2-(2,4 -DICHLOROPHENYL)ETHOXY)BENZAMIDE; ANTITHROMBOTICS; CARDIOVAS-CULAR DISORDERS LIKE THROMBOEMBOLICS OR RESTENOSES; REVERSI-BLE INHIBITORS OF BLOOD CLOTTING ENZYMES FACTOR XA, VIIA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| EP-1228039-A1 | N-GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032611-A1 | N-GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-10 | — | — | WO | disclosed |
| EP-1095933-A1 | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162967-A1 | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | F7, GUCY1A2, F9 | F10 20/4885HDAC8 1804/4885LMNA 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.